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Abstract: Endostar, a novel recombinant human endostatin, which was approved by the 
Chinese State Food and Drug Administration in 2005, has a broad spectrum of activity against 
solid tumors. In this study, we aimed to determine whether the anticancer effect of Endostar is 
increased by using a nanocarrier system. It is expected that the prolonged circulation of endostar 
will improve its anticancer activity. Endostar-loaded nanoparticles were prepared to improve 
controlled release of the drug in mice and rabbits, as well as its anticancer effects in mice with 
colon cancer. A protein release system could be exploited to act as a drug carrier. Nanoparticles 
were formulated from poly (ethylene glycol) modified poly (DL-lactide-co-glycolide) (PEG-
PLGA) by a double emulsion technique. Physical and release characteristics of endostar-  loaded 
nanoparticles in vitro were evaluated by transmission electron microscopy (TEM), photon cor-
relation spectroscopy (PCS), and micro bicinchoninic acid protein assay. The pharmacokinetic 
parameters of endostar nanoparticles in rabbit and mice plasma were measured by enzyme-linked 
immunosorbent assay. Western blot was used to detect endostatin in different tissues. To study 
the effects of endostar-loaded nanoparticles in vivo, nude mice in which tumor cells HT-29 
were implanted, were subsequently treated with endostar or endostar-loaded PEG-PLGA nano-
particles. Using TEM and PCS, endostar-loaded PEG-PLGA nanoparticles were found to have 
a spherical core-shell structure with a diameter of 169.56 ± 35.03 nm. Drug-loading capacity 
was 8.22% ± 2.35% and drug encapsulation was 80.17% ± 7.83%. Compared with endostar, 
endostar-loaded PEG-PLGA nanoparticles had a longer elimination half-life and lower peak 
concentration, caused slower growth of tumor cell xenografts, and prolonged tumor doubling 
times. The nanoparticles changed the pharmacokinetic characteristics of endostar in mice and 
rabbits, thereby reinforcing anticancer activity. In conclusion, PEG-PLGA nanoparticles are a 
feasible carrier for endostar. Endostar-loaded PEG-PLGA nanoparticles seem to have a better 
anticancer effect than conventional endostar. We believe that PEG-PLGA nanoparticles are an 
effective carrier for protein medicines.
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Background
Cancer affects millions of men and women in all age groups. Colorectal cancer is one of 
the most common internal malignancies. However, many conventional chemotherapies 
are ineffective in colorectal cancer, and in many other cancers, because of short half-
lives and inability to reach the tumor site in effective concentrations.1 The emergence of 
nanotechnology has had a profound effect on chemotherapy for   cancer. To date, many 
anticancer drugs have been incorporated into polymeric micelles,   surface-modified 
particles, liposomes, or nanoparticles for delivery to the tumor.2,3 There have been 
several problems with these approaches, including limited   biodistribution, toxic side International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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effects, and rapid clearance by the reticuloendothelial sys-
tem. However, nanoparticles are different from other drug 
carriers, with many potential chemotherapeutic advantages, 
including convenient injection, deposition in target tis-
sues, an enhanced targeting effect in primary or metastatic 
tumors, and reduction of toxicity to normal tissues.4–6 In 
addition, poly(ethylene glycol) modified poly (DL-lactide-
co-glycolide) (PEG-PLGA) nanoparticles can incorporate 
water-soluble anticancer drugs and reduce drug interaction 
within the reticuloendothelial system. Moreover, poly(DL-
lactide-co-glycolide) (PLGA) and poly(ethylene glycol) 
(PEG), which are hydrophilic-hydrophobic diblock copoly-
mers, are biodegradable, nontoxic,7 nonimmunogenic, and 
often act as drug incorporation sites.
Endostatin, a 20 kDa internal fragment of the carboxyter-
minus of collagen XVIII, has been demonstrated to inhibit 
the growth of a variety of human tumors by inhibiting 
neovascularization.8,9 However, most available endostatins 
are either unstable or expensive, which limits their clinical 
application. Endostar, a novel recombinant human endosta-
tin, was expressed and purified in Escherichia coli. It was 
approved by the Chinese State Food and Drug Administra-
tion for the treatment of nonsmall cell lung cancer in 2005 
and has a broad spectrum of activity against solid tumors. 
Endostar had been shown to inhibit endothelial cell prolif-
eration, migration, and vessel formation.9 Moreover, it is 
more stable than conventional endostatin, because it has an 
additional nine-amino acid sequence at the N terminus of 
the protein.10,11
In this study, we hypothesized that PEG-PLGA nano-
carrier systems could increase the circulation half-life of 
endostar by exploiting the enhanced permeation retention 
phenomenon effectively, and thus increase the effect of 
the drug.
Materials and methods
Materials
Endostar (5 mg/mL) was provided by Shandong Simcere 
Medgenn Bio-Pharmaceutical Co Ltd (Nanjing, China). 
PEG-PLGA was purchased from the Shandong Institute of 
Medical Instruments (Shandong, China). The molar ratio 
of D, L-lactic to glycolic acid of PLGA (molecular weight 
45 kDa) was 50:50. Every 10 g of PEG-PLGA contained 1 g 
PEG (molecular weight 2 kDa). Polyvinyl alcohol (molecular 
weight 13–23 kDa) was obtained from Sigma-Aldrich (St 
Louis, MO). The primary antibodies for CD-31, endostatin, 
vascular endothelial growth factor, and β-actin were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA). 
The S-P detection kit was purchased from Fuzhou Maixin 
Co (Fujian, China). All other chemicals were analytic grade. 
Double-distilled water was used throughout the study. The 
apparatus, including a low-temperature ultracentrifuge 
(Hitachi, Japan), transmission electron microscopy (TEM, 
Philips, The Netherlands), photon correlation spectroscopy 
(PCS, Malvern, UK), ultraviolet spectrophotometer (Spec-
trum China Ltd, Shanghai, China), and an enzyme-linked 
immunosorbent assay (ELISA) reader (BioTek, Winooski, 
VT) were used. New Zealand rabbits (2–3 kg) and BALB/c 
nude mice (4–6 weeks of age, 10–25 g) were purchased from 
the Animal Center of Shandong University, Shangdong, 
China, and Hunan Slac Laboratory Animal Co Ltd, Hunan, 
China, respectively. All work performed with the animals 
was in accordance with and approved by the ethics committee 
of Shandong University.
synthesis of Peg-PLgA nanoparticles
PEG-PLGA nanoparticles were prepared by a double emul-
sion (mixing solvent) method as described in previous 
studies.12,13 Firstly, PEG-PLGA was dissolved in dichlo-
romethane. The first emulsion (o/w) was formed between a 
dichloromethane solution of PEG-PLGA (1 mL) and endostar 
solution (0.05 mL) by shearing (2800 rpm for 60 seconds). 
Then a 2 mL aqueous solution containing 0.1% polyvi-
nyl alcohol was added into this primary w/o emulsion to 
obtain the double emulsion (w/o/w) by high-speed shearing 
(25000 rpm for 60 seconds). The solvent was evaporated in 
aqueous solution 10 mL containing 0.1% polyvinyl alcohol 
(w/v) either by gentle magnetic stirring at room temperature 
or using a vacuum rotating evaporator. Nanoparticles were 
recovered by centrifugation (40000 rpm for 40 minutes) and 
washed three times in phosphate-buffered saline.
Entrapment efficiency
After dissolving the lyophilized nanospheres in 0.05 N NaOH 
and 1% sodium dodecyl sulfate, the endostar content of the 
nanoparticles was estimated using the micro bicinchoninic 
acid protein assay.14 No interference with the PEG-PLGA 
or stabilizers was observed. The assay was validated using 
purified recombinant human endostatin with a detection 
limit of 0.5–20 µg/mL. The concentration of endostar in the 
supernatant (C) was calculated according to the standard 
curve equation. The drug-loading capacity and entrapment 
efficiency were expressed as follows:
Endostar loading capacity (%)  
= Mendostar/Mendostar–loaded PEG–PLGA nanoparticles × 100
Endostar encapsulation (%) = Mendostar/Mendostar devoted × 100International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Mendostar was the drug amount in the nanoparticles   
[Mendostar = C × V, C: concentration in the supernatant,   
V: volume]; Mendostar-loaded PEG-PLGA nanoparticles was the amount 
of PEG-PLGA nanoparticles containing endostar; and 
Mendostar devoted was the initial amount of Endostar.
Particle size analysis
Morphologic examination of the nanoparticles was performed 
using TEM. Particle size distribution, ie, mean diameter and 
polydispersity index (PDI) was determined by PCS. The PDI 
was calculated as follows:
PDI = Mw/Mn ⋅ (Mw : the weight average molecular 
weight; Mn : the number average molecular weight)
The presence of residual polyvinyl alcohol on the surface 
of the nanoparticles was determined by direct and indirect 
methods.15 The nanoparticles were digested in 0.05 N NaOH 
and 1% sodium dodecyl sulfate. The solution obtained was 
then neutralized using HCl diluted with phosphate-buffered 
saline (pH 7.4), and analyzed for polyvinyl alcohol content 
using the colorimetric method. Absorbance of the formation 
of polyvinyl alcohol-iodine complexes was determined in the 
presence of boric acid at 620 nm. The residual polyvinyl alco-
hol was also calculated according to the difference between the 
total amount used and the amount present in the supernatant of 
the washing steps. Corrections were made for the PEG-PLGA 
nanoparticles, because PEG resulting from polymer degrada-
tion would interfere with the polyvinyl alcohol dosage.
In vitro release
Endostar-loaded nanoparticles were washed three times with 
phosphate-buffered saline and added to a dialysis Eppendorf 
tube with phosphate-buffered saline (pH 7.4, 0.01% sodium 
azide, 0.02% Tween 80). The Eppendorf tube was stirred at 
100 rpm and at 37°C. At indicated time intervals, the suspension 
was centrifuged at 40000 rpm for 40 minutes.14 The supernatant 
was removed and detected using the micro bicinchoninic acid 
protein assay with an ultraviolet spectrophotometer at 562 nm, 
and new phosphate-buffered saline dialysis media was added 
to the Eppendorf tube. The endostar released into the replaced 
phosphate-buffered saline was calculated at different time inter-
vals according to the standard curve, which was established by 
purified recombinant human endostatin. The release curve of 
endostar-loaded nanoparticles was then described.
Pharmacokinetic study  
of endostar-loaded nanoparticles in vivo
Forty male BALB/c mice (mean weight 0.021 kg) were admin-
istered a single intravenous bolus of endostar or endostar-loaded 
nanoparticles via the tail vein at a dose of 90 mg/m2 (n = 20 
per dose group). Blood samples were   collected by retro-orbital 
bleeding from the two groups at the indicated time intervals. 
Because blood samples could not be collected from the same 
mouse repeatedly over a short time period, several mice died 
after collection of blood, and New Zealand rabbits were used 
subsequently. Ten New   Zealand rabbits were randomized 
into two groups. After 12 hours of fasting, a bolus of the 
sample equivalent to 90 mg/m2 endostar or endostar-loaded 
nanoparticles, was administered intravenously to each rabbit. 
Each rabbit was given an equal amount of endostar intrave-
nously. Blood samples were collected from the aural vein at 
the indicated time intervals. After centrifugation, the plasma 
supernatant was detected by ELISA. The assay was validated 
using purified recombinant human endostatin with a detection 
limit of 2–500 ng/mL. The concentrations of endostar were 
calculated according to the standard curve, established using 
a standard endostar solution. The pharmacokinetic parameters 
for Endostar distribution were calculated by using the DAS 
2.0 program.16
Amount of endostatin  
in different tissues in vivo
In order to determine the clearance efficacy in the body, 
the amounts of endostar in different tissues were analyzed 
by Western blot assay using a polyclonal antiendostatin 
antibody.16 Male BALB/c mice were used in this step. Each 
mouse was administered an intravenous dose once and then 
sacrificed at predetermined times (10 minutes or three hours). 
Tissue samples of liver, spleen, and lung were collected, 
weighed, and homogenated. The supernatant protein were 
then concentrated and subjected to sodium dodecyl sulfate–
polyacrylamide gel electrophoresis followed by Western blot 
assay with a polyclonal antihuman endostatin antibody.
Tumor inhibition effect  
of endostar-loaded nanoparticles in vivo
The therapeutic efficacy and biocompatibility of endostar-
loaded nanoparticles was evaluated in vivo by using a cancer 
model. HT-29 colon cancer cells suspended at a density of 
108 cells/mL were inoculated subcutaneously in the right flank 
of BALB/c nude mice.17 After xenografts reached about 5 mm 
in diameter, the nude mice were randomly assigned to four 
treatment groups (n = 8 each), ie, control, endostar, endostar-
loaded nanoparticles, and blank PEG-PLGA nanoparticles. 
Then, based on clinical dosing in humans, endostar 7.5 mg/m2/
day was administered intravenously once a day during the 
first two weeks of the treatment cycle.   Endostar-loaded International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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nanoparticles containing the same amount of endostar were 
injected every seven days to investigate the effect of con-
trolled release in the endostar-loaded nanoparticle group. In 
the control group, the same volume of   phosphate-buffered 
saline or blank PEG-PLGA nanoparticles was injected. Mice 
were sacrificed on day 21. During the program, tumor size 
was measured by calipers (length and width) every three days. 
The tumor volume (V = 1/2 × length × width2) was calculated 
and the tumor growth curve was generated.17,18 The tumor 
doubling time during the logarithmic phase of tumor growth 
and inhibition rate on day 21 was calculated. The inhibition 
rate was calculated as follows:
Inhibition rate (%) =   (1−Volume of experiment group/ 
Volume of control group) × 100
In addition, the amount of endostar and vascular endothe-
lial growth factor in the tumors was also analyzed by Western 
blot assay.
Immunohistochemistry
Tumor tissue specimens were fixed in neutral formalin and 
embedded in paraffin after collection from the sacrificed 
mice. Tissue sections 5 µm thick were dewaxed and incu-
bated with 0.01 M natrium citricum for antigen retrieval. The 
slides were rinsed in phosphate-buffered saline and incubated 
overnight at 4°C with diluted anti-CD31 antibody. Steps were 
then performed using the immunostain kit according to the 
manufacturer’s instructions. The sections were examined at a 
magnification of 100 (10 objective and 10 ocular lens) under 
a light microscope to identify three regions with the highest 
microvascular density. Microvessels were counted in these 
areas at a magnification of 200× , and the average numbers 
of microvessels were recorded. The average number was the 
microvascular density of the tumor.19
statistical analysis
In all cases, experiments were done in triplicate and data 
represented as mean ± standard deviation. The inhibitory 
effect on tumor growth was analyzed by one-way analysis 
of variance and Student’s t-test.18 P , 0.05 was considered 
statistically significant in all cases.
Results
characteristics of endostar-loaded 
nanoparticles
In this study, the standard calibration curve equation for the 
concentration of endostar in the supernatant (C) was assayed 
using the micro bicinchoninic acid protein assay:
OD = 0.004C + 0.0556 (n = 3, r = 0.9996) (OD, optical 
density value of absorbance).
The lower limit of determination was 0.5 µg/mL. The 
intraday relative standard deviation and interday relative 
standard deviation were less than 5%, justifying use of this 
method for measurement of endostar concentration. Drug 
loading capacity was 8.22% ± 2.35% and drug encapsulation 
of the endostar-loaded nanoparticles was 80.17% ± 7.83%. 
The morphology of endostar-loaded nanoparticles was found 
to be a spherical core-shell structure with a relatively smooth 
surface (Figure 1). It was approximately 169.56 ± 35.03 nm 
in diameter (Figure 2). The PDI was 0.47 ± 0.18 by photon 
correlation spectroscopy. Residual polyvinyl alcohol on the 
surface was not detected by the two different methods.
release of endostar-loaded nanoparticles 
in phosphate-buffered saline
Endostar release from the endostar-loaded nanoparticles in 
phosphate-buffered saline (pH 7.04) is shown as a standard 
curve equation for the endostar solution in Figure 3. The 
endostar release profile was biphasic, with an initial abrupt 
Figure 1 The core-shell structure of endostar-loaded Peg-PLgA nanoparticles. 
Transmission electron microscopy showed that nanoparticles were round particles 
with relative smooth edges.
Abbreviation:  Peg-PgLA,  poly(ethylene  glycol)  modified  poly(DL-lactide-co-
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the endostar-loaded nanoparticles are illustrated in Figure 4. 
The concentration of endostar in the endostar group was 
about four times that in the PEG-PLGA nanoparticle group 
at 10 minutes after intravenous administration. Endostar was 
removed quickly from the circulation in the endostar group. In 
contrast, its removal was slow in the endostar-loaded nanopar-
ticle group. The distribution half-life time (t1/2α) and terminal 
elimination half-life (t1/2β) of endostar were 2.86 ± 0.53 hours 
and 27.95 ± 8.28 hours, respectively, in the endostar-containing 
nanoparticle group, and 0.57 ± 0.13 hours and 2.67 ± 1.30 hours 
in the endostar group. The area under the curve was 
72628.86 ± 7522.48 ng/ml*h in the endostar-loaded nanopar-
ticle group and 20574.67 ± 8081.93 ng/ml*h in the endostar 
group. The peak concentration (Cmax) was 3.87 ± 0.46 µg/mL 
and 11.81 ± 4.57 µg/mL, respectively. The plasma concentra-
tion was 7.4–84.7 µg/L between day 5 and day 10.
Although data were collected only during the first 
two days for mice, a similar clearance was shown in the 
two groups (Figure 5). The t1/2α and t1/2β of endostar were 
4.83 ± 1.31 hours and 24.79 ± 9.36 hours, respectively, in the 
endostar-loaded nanoparticle group, and 0.29 ± 0.18 hours 
and 1.21 ± 0.96 hours in the endostar group.
Amount of endostatin  
in different tissues in vivo
The relative content of endostatin in the endostar group at 
10 minutes was 45.5 ± 3.5 in lung, 36.7 ± 4.2 in liver, and 
48.7 ± 5.9 in spleen, and was 133 ± 19.6, 127 ± 21.7, and 
112 ± 15.4, respectively, in the endostar-loaded nanoparticle 
group. The relative endostatin levels in the endostar-loaded 
nanoparticle group at three hours was 7.5 ± 4.1 in lung, 
9.3 ± 7.2 in liver, and 13 ± 11.9 in spleen, but was not detected 
in the endostar group (Figure 6). The levels of endostatin 
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Figure 3 release of endostar from Peg-PLgA nanoparticles in phosphate-buffered 
saline (pH 7.4, 0.01% sodium azide, 0.02% Tween 80). The error bars represent 
mean ± standard deviations of experiments performed in triplicate.
Abbreviation:  Peg-PgLA,  poly(ethylene  glycol)  modified  poly(DL-lactide- 
co-glycolide).
release and a subsequent sustained release. Abrupt release 
occurred at two hours after injection, and 5.0% ± 1.09% of 
the loaded endostar was released after the first 24 hours. 
Almost 90% of the loaded endostar was still enveloped in 
the nanoparticles after 96 hours. The amount of cumulated 
endostar release was 24.2% on day 21.
Pharmacokinetic characteristics  
of endostar-loaded nanoparticles
The standard curve for endostar in plasma was derived from 
the following equation:
y =   0.01x + 0.087 (r . 0.9994, Y: optical density  
value of absorbance, X: the concentration).
The limit of determination was 2 µg/L. Mean plasma 
concentrations in rabbits over time for the free endostar and 
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and vascular endothelial growth factor in tumor tissue in 
the endostar-loaded nanoparticle group were 21.5 ± 11.9 
and 0, respectively, and were 10.6 ± 5.3 and 4.6 ± 2.7 in the 
endostar group (Figure 7).
Tumor inhibition effect  
of endostar-loaded nanoparticles in vivo
The tumor formation rate was 100% in the study. No deaths 
and no metastases in organs were found during treatment, 
and all mice were alive without dyscrasia. There was no 
significant difference in the body weight of mice between 
the four groups before and after treatment. All tumors 
continued to grow after injection, and many started to 
regress on day 5. As shown by the tumor growth curve of 
HT-29 cell xenografts, xenograft growth was fast in the 
blank and control groups, but was significantly depressed 
in the endostar and endostar nanoparticle-treated groups 
(Figure 8). Tumor doubling time was prolonged in the treat-
ment group (4.1 days in the endostar group and 5.5 days in 
endostar-loaded nanoparticle group versus 3.18 days in the 
blank control group and 3.27 days in the blank nanoparticle 
group). The inhibition rate was 58.56% in the endostar 
group, 77.75% in the endostar-loaded nanoparticle group, 
and 8.97% in the blank nanoparticle group. The tumor 
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Figure 5 Mean plasma concentration of endostar following a single intravenous 
administration of endostar or endostar-loaded Peg-PLgA nanoparticles at 90 mg/
m2 in mice.
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volumes of the endostar, endostar-loaded nanoparticle, 
blank nanoparticle, and phosphate-buffered saline groups 
on day 21 were 1.613 ± 0.448 cm3, 0.866 ± 0.341 cm3, 
3.543 ± 0.640 cm3, and 3.892 ± 1.076 cm3, respectively 
(Figure 9). No significant toxicity was observed in any of 
the four groups.
Microvascular density in the tumors was reduced after 
treatment. Microscopic observations are shown in Fig-
ure 10. The amount of microvessels in the endostar-loaded 
nanoparticle group was significantly lower than that in the 
endostar group (6 ± 2.3 versus 15 ± 5.1, P , 0.05), and was 
also lower than in the control (43 ± 6.7) and PEG-PLGA 
nanoparticle groups (56 ± 7.3, P , 0.01).
Discussion
Although endostar microsphere and protein drug-loaded 
PEG-PLGA nanoparticles had been reported,20,21 we have 
prepared a new nanoparticle, ie, the endostar-loaded PEG-
PLGA nanoparticle, and investigated its characteristics in 
this study. Endostar-loaded PEG-PLGA nanoparticles are 
approximately 169.56 ± 35.03 nm in diameter. They are 
smaller than conventional microspheres, can be admin-
istered intravenously, and accumulate readily in tumors. 
It was demonstrated that endothelial cells in tumors 
were distinct from those in normal tissues, possessing 
wide fenestrations, ranging from 200 nm to 1.2 mm. 
The vascular pore size of the LS174T tumor, a human 
colon adenocarcinoma, may be as large as 400 nm. This 
large pore size allows passage of nanoparticles into the 
extravascular space.22 There is increased extravasation 
and accumulation of drug from the tumor vasculature into 
the tumor cells, attributed to the enhanced permeability 
of tumor endothelium and lack of lymphatic drainage in 
tumor cells.
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Figure 8 Tumor growth of HT-29 cell xenografts after treatment with endostar or 
endostar-loaded Peg-PLgA nanoparticles.
Abbreviation:  Peg-PgLA,  poly(ethylene  glycol)  modified  poly(DL-lactide-co-
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Figure 9 suppression of HT-29 tumor growth in nude mice. A) endostar-loaded Peg-
PLgA nanoparticle group. B) endostar group. C) Blank Peg-PLgA nanoparticle group. 
D) Phosphate-buffered saline blank control group. There is no statistically significant 
difference between C and D; however, A and B is significantly different from D. 
Abbreviation:  Peg-PgLA,  poly(ethylene  glycol)  modified  poly(DL-lactide-co-
glycolide)
Figure  10  Histologic  slice  obtained  from  animal  treated  with  endostar-loaded 
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Endostar is a 20 kDa peptide and different from protein 
drugs which are encapsulated within PLGA or PEG-PLGA 
nanoparticles.21,23 It is smaller than a protein molecule and 
more difficult to encapsulate. Thus, PEG and PLGA, which 
are hydrophilic-hydrophobic diblock copolymers, were used 
in this study. They have great potential as vehicles for the 
delivery of anticancer drugs.24,25 PLGA, the hydrophobic 
moiety, is biodegradable and acts as a drug incorporation 
site. PEG, the hydrophilic moiety, is a nontoxic, nonimmu-
nogenic, and hydrophilic polymer which can prevent interac-
tions with cells and proteins.26,27 Studies have revealed that 
nanoparticles of 100 nm in thickness with a PEG layer more 
than 10 nm in thickness are not easily engulfed by phago-
cytes (Figure 11).28,29 Because of the hydrophilic moiety, the 
encapsulation of endostar-loaded nanoparticles was high at 
80.17% ± 7.83%.
Moreover, PEG-PLGA nanoparticles hydrolyze in 
an aqueous environment (hydrolytic degradation or 
biodegradation).30 The biodegradation rates of PLGA copo-
lymers are dependent on the molar ratio of the lactic and 
glycolic acids in the polymer chain. Thus, PEG-PLGA nano-
particles have been used for controlling the release of drugs, 
altering pharmacokinetics, enhancing anticancer effect, and 
decreasing toxicity, especially for water-insoluble drugs.31–33 
Similar to most proteins, endostar is administered by mul-
tiple injections at a high dose in order to maintain adequate 
therapeutic levels.34,35 Clinically, endostar is administered 
intravenously at a dose of 7.5 mg/m2 per day during the first 
two weeks of a treatment cycle. However, the plasma concen-
tration of endostar would still fluctuate because of its short 
biologic half-life and rapid metabolism. In addition, the need 
for multiple injections causes poor patient compliance, which 
limits its clinical use. However, PEG-PLGA nanoparticles 
change the pharmacokinetic characteristics of endostar, with 
the t1/2α and t1/2β of endostar-containing nanoparticles being 
longer than for endostar (P , 0.05) and the area under the 
curve and maximum concentration being larger than for 
endostar (P , 0.05).
As shown by Western blot assay, the amounts of endosta-
tin detected in the liver, spleen, and lung in the Endostar-
containing PEG-PLGA nanoparticle group were larger than 
that in the endostar group after 10 minutes. There was no 
statistically significant difference between amounts detected 
in liver and spleen, although the amount of endostatin in 
lung was higher than in liver or spleen. Endostatin was 
detected only in the endostar-loaded PEG-PLGA group at 
three hours after intravenous injection. Even when the mice 
were sacrificed, the amount of endostatin in tumors for the 
endostar-loaded nanoparticle group was larger than for the 
endostar group.
The anticancer effect of endostar was improved when 
incorporated into PEG-PLGA nanoparticles. As shown 
in the colon cancer model, tumor doubling time was pro-
longed in the endostar-loaded nanoparticle group. The 
inhibition rate for endostar-loaded nanoparticles was higher 
than for endostar alone (P , 0.05). The tumor volumes 
of the endostar and endostar-loaded nanoparticle-treated 
groups were significantly smaller than those of the con-
trol and blank PEG-PLGA nanoparticle control groups 
(P , 0.01). There was no significant difference in tumor 
inhibition between the two control groups (P . 0.05). 
Because endostar can inhibit neovascularization or induce 
apoptosis of vascular endothelium to kill tumor cells,36 
microvascular density was reduced in tumors after treat-
ment with endostar-loaded nanoparticles. The formation 
of new capillaries in the existing vasculature is a process 
fundamental to the development of a solid tumor, and it 
was hard to elicit angiogenesis in the tumors treated with 
endostar, and they did not grow fast. The antiangiogenic 
effect of endostatin is related to vascular endothelial growth 
factor.8 The amount of vascular endothelial growth factor 
in tumors for the endostar-loaded nanoparticle group was 
found to be less than for the endostar group when the mice 
were sacrificed (P , 0.05).
PEG-PLGA nanoparticles could maintain adequate 
concentrations of endostar in plasma and tumor, thereby 
improving its antitumor effect. PEG-PLGA nanoparticles 
have a great potential to be protein drug carriers. Although 
more of their characteristics need to be investigated, and 
PEG
PEG
PLGA
Endostar
Figure 11 endostar-loaded nanoparticles with a Peg layer.
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some disadvantages need to be overcome, including passive 
targeting, low drug-loading capacity, and sensitization, PEG-
PLGA nanoparticles could be modified to be specific for 
cancer and applied in the clinical setting as a protein carrier 
system in the future.
Conclusion
In this study, we prepared endostar-loaded PEG-PLGA 
nanoparticles in an innovative way and found that they were 
useful for sustained release of endostar. Although many other 
characteristics need to be investigated, endostar-loaded PEG-
PLGA nanoparticles may improve the anticancer activity 
of endostar by changing the pharmacokinetic behavior of 
endostar in vivo.
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